In addition, serious questions were raised about the completeness and homogeneity of PV and other MPN cases reported to cancer registries, resulting in part from the recent addition of the JAK2 mutation to the diagnosis criteria. This evidence concerns the gene JAK2 and myeloproliferative disorder.